BYL719 (alpelisib) for use in the treatment of PIK3CA-related overgrowth spectrum (PROS-CLOVES syndrome)

Patent metadata

Field	Value
Publication number	US-12427141-B2
Application number	US-202217721067-A
Country	US
Kind code	B2
Filing date	Apr 14, 2022
Priority date	Feb 19, 2016
Publication date	Sep 30, 2025
Grant date	Sep 30, 2025

Abstract

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

First claim

The invention claimed is:

1. A method of treating a patient who is an adult having a PIK3CA-related overgrowth spectrum (PROS) disorder, comprising the steps of
identifying the subject as suffering from the PROS disorder having an overgrowth of multiple organs or tissues caused by a somatic mosaic mutation, wherein the PROS disorder is not an isolated venous malformation;
administering orally to the subject a therapeutically effective amount of BYL719, wherein the therapeutically effective amount of BYL719 is a starting dose of 250 mg daily; and
reversing the overgrowth of multiple organs or tissues.

2. The method of claim 1 , wherein the somatic mosaic mutation is a mutation in the PIK3CA gene selected from the group consisting of H1047R, E542K and E545K.

3. The method of claim 1 , wherein the PROS disorder is not responsive to treatment with rapamycin.

4. The method of claim 1 , wherein the PROS disorder is selected from the group consisting of
fibroadipose overgrowth;
megalencephaly-capillary malformation syndrome;
congenital lipomatous overgrowth, vascular malformations, epidermal nevi, skeletal and spinal anomalies and/or scoliosis (CLOVES) syndrome;
hemihyperplasia multiple lipomatosis; and
Klippel-Trenaunay syndrome.

5. The method of claim 4 , wherein the PROS disorder is congenital lipomatous overgrowth, vascular malformations, epidermal nevi, skeletal and spinal anomalies, and/or scoliosis (CLOVES) syndrome.

6. The method of claim 4 , wherein the PROS disorder is Klippel-Trenaunay syndrome.

7. The method of claim 1 , wherein the method treats a symptom selected from the group consisting of edema, venous dilation, vascular tumors, elevated brain natriuretic peptide blood level, proteinuria, kidney dysfunction, overgrown tissue, dysregulated adipose tissue, scoliosis, enlarged bony structures without progressive bony overgrowth, benign tumors, megalencephaly-capillary malformation, lipomatous asymmetric overgrowth of the trunk, epidermal nevi, lymphatic malformation, muscle hypertrophy, liver steatosis, and spleen disorganization.

8. A method of treating a patient who is a child having a PIK3CA-related overgrowth spectrum (PROS) disorder, comprising the steps of
identifying the subject as suffering from the PROS disorder having an overgrowth of multiple organs or tissues caused by a somatic mosaic mutation, wherein the PROS disorder is not an isolated venous malformation;
administering orally to the subject a therapeutically effective amount of BYL719, wherein the therapeutically effective amount of BYL719 is a starting dose of 50 mg daily; and
reversing the overgrowth of multiple organs or tissues.

9. The method of claim 8 , wherein the somatic mosaic mutation is a mutation in the PIK3CA gene selected from the group consisting of H1047R, E542K and E545K.

10. The method of claim 8 , wherein the PROS disorder is not responsive to treatment with rapamycin.

11. The method of claim 8 , wherein the PROS disorder is selected from the group consisting of
fibroadipose overgrowth;
megalencephaly-capillary malformation syndrome;
congenital lipomatous overgrowth, vascular malformations, epidermal nevi, skeletal and spinal anomalies and/or scoliosis (CLOVES) syndrome;
hemihyperplasia multiple lipomatosis; and
Klippel-Trenaunay syndrome.

12. The method of claim 11 , wherein the PROS disorder is congenital lipomatous overgrowth, vascular malformations, epidermal nevi, skeletal and spinal anomalies, and/or scoliosis (CLOVES) syndrome.

13. The method of claim 11 , wherein the PROS disorder is Klippel-Trenaunay syndrome.

14. The method of claim 8 , wherein the method treats a symptom selected from the group consisting of edema, venous dilation, vascular tumors, elevated brain natriuretic peptide blood level, proteinuria, kidney dysfunction, overgrown tissue, dysregulated adipose tissue, scoliosis, enlarged bony structures without progressive bony overgrowth, benign tumors, megalencephaly-capillary malformation, lipomatous asymmetric overgrowth of the trunk, epidermal nevi, lymphatic malformation, muscle hypertrophy, liver steatosis, and spleen disorganization.

Assignees

• Inst Nat Sante Rech Med
• Centre Nat Rech Scient
• Univ Paris Cite
• Assist Publique—Hopitaux De Paris Aphp

Inventors

• Canaud Guillaume

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/14

  Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P19/00

  Drugs for skeletal disorders · CPC title

• A61K31/4439 Primary

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title